We’re excited to welcome Yujiro Hata, President & CEO of IDEAYA Biosciences, to Hexagon Bio’s Board as we advance our pipeline of novel ADCs toward the clinic! Leveraging our discovery platform, which integrates machine learning, genomics, chemistry, and synthetic biology to mine the global metagenome, we have identified a broad spectrum of next-generation natural product-based cytotoxic payloads for antibody-drug conjugates (ADCs). These innovations are driving our pipeline of ADC programs to address significant unmet needs in solid tumors and hematologic malignancies. Read press release: https://bit.ly/3V99rja #cancer #oncology #cancermedicines #antibodydrugconjugates #ADCs #metagenome #genome?
Hexagon Bio
生物技术研究
Menlo Park，California 4,488 位关注者
Discovering novel medicines in the global metagenome and bringing them to patients
关于我们
Hexagon Bio is a biopharmaceutical company pioneering the discovering novel payloads for antibody-drug conjugates (ADCs) to address critical unmet needs in oncology. Leveraging a proprietary platform, the company mines cytotoxic small molecules from microbial genomes for use as ADC payloads. Advances in DNA sequencing have enabled the identification of both existing ADC payloads—such as topoisomerase and tubulin inhibitors—and novel payload mechanisms targeting essential cancer pathways such as protein translation. Hexagon Bio is advancing a pipeline of next-generation ADC candidates with novel payloads designed to treat a wide range of solid tumors and hematological malignancies.
- 网站
-
https://www.hexagonbio.com/#about
Hexagon Bio的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Menlo Park，California
- 类型
- 私人持股
地点
-
主要
获取路线
1490 OBrien Dr
US，California，Menlo Park，94025
Hexagon Bio员工
动态
-
We’re thrilled to announce the appointment of industry leader Yujiro Hata to Hexagon Bio’s Board of Directors!?An entrepreneur with over 25 years of experience building companies that have advanced innovative therapies, Yujiro currently serves as President and CEO of IDEAYA Biosciences. We look forward to Yujiro’s strategic insights and contributions as we advance our pipeline of novel antibody-drug conjugates (ADCs) leveraging next-generation natural product-based payloads to address significant unmet needs in cancer. Read press release: https://bit.ly/3V99rja #cancer #oncology #cancermedicines #antibodydrugconjugates #ADCs #metagenome #genome
-